DA32 Life Science Tech Acquisition

General Information
Business:

We intend to capitalize on our management team’s background and experience to identify promising opportunities in the life sciences sector. We are offering Class A ordinary shares. (This is NOT a unit offering; most blank-check or SPAC IPOs are unit offerings.)

Our CEO is Steven Kafka, Ph.D., a managing partner at Section 32, a venture capital fund.

We are sponsored by Deerfield Management, ARCH Venture Partners and Section 32.

(Note: DA32 Life Science Tech Acquisition priced its SPAC IPO on July 27, 2021, in line with the terms in its prospectus: 20 million Class A ordinary shares at $10 each to raise $200 million.) 

Industry: BLANK CHECKS
Employees: 0
Founded: 2021
Contact Information
Address 345 Park Avenue South, 12th Floor New York, NY 10010, US
Phone Number (212) 551-1600
Web Address
View Prospectus: DA32 Life Science Tech Acquisition
Financial Information
Market Cap $256.5mil
Revenues $0 mil (last 12 months)
Net Income $0 mil (last 12 months)
IPO Profile
Symbol DALS
Exchange NASDAQ
Shares (millions): 20.0
Price range $10.00 - $10.00
Est. $ Volume $200.0 mil
Manager / Joint Managers JPMorgan/ Cowen
CO-Managers -
Expected To Trade: 7/28/2021
Status: Priced
Quiet Period Expiration Date:
Lock-Up Period Expiration Date:
SCOOP Rating
Rating Change